Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial

Autor: Bögemann, Martin, Shore, Neal D., Smith, Matthew R., Tammela, Teuvo L.J., Ulys, Albertas, Vjaters, Egils, Polyakov, Sergey, Jievaltas, Mindaugas, Luz, Murilo, Alekseev, Boris, Lebret, Thierry, Schostak, Martin, Verholen, Frank, Le Berre, Marie-Aude, Srinivasan, Shankar, Ortiz, Jorge, Mohamed, Ateesha F., Sarapohja, Toni, Fizazi, Karim

Publikováno v: In European Urology March 2023 83(3):212-221

Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial

Autor: Smith, Matthew R., Shore, Neal, Tammela, Teuvo L., Ulys, Albertas, Vjaters, Egils, Polyakov, Sergey, Jievaltas, Mindaugas, Luz, Murilo, Alekseev, Boris, Kuss, Iris, Le Berre, Marie-Aude, Mohamed, Ateesha F., Odom, Dawn, Bartsch, Jennifer, Snapir, Amir, Sarapohja, Toni, Fizazi, Karim

Publikováno v: In European Journal of Cancer September 2021 154:138-146

Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP).

Autor: Chehrazi-Raffle, Alex, Morgans, Alicia K., Gschwend, Jürgen E., Shore, Neal D., Ross, Ashley, Feng, Felix Y, Hope, Thomas A., Trandafir, Lucia, Kuss, Iris, Le Berre, Marie-Aude, Joensuu, Heikki, Fizazi, Karim

Publikováno v: Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, pTPS254-TPS254, 235p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Eficacia y Seguridad de Regorafenib en Pacientes con Características de Buen Pronóstico en Tratamiento del Cáncer Colorrectal Metastásico: Análisis de Subgrupo del Estudio CORRECT

Autor: Palhares, Rodrigo Resende, Britto, Glauco do Canto, Su, Yun, Le Berre, Marie-Aude, Henriques, Ricardo Saad, Navachi, Fabricio Volpato, Pereira, Daniela Cristina Foli, Ostojic, Helene, Azevedo, Graziella Agostini, Van Cutsem, Eric

Publikováno v: Revista Brasileira de Cancerologia; Vol. 68 No. 4 (2022): Oct./Nov./Dec.; e-162727
Revista Brasileira de Cancerologia; Vol. 68 Núm. 4 (2022): oct./nov./dic.; e-162727
Revista Brasileira de Cancerologia; v. 68 n. 4 (2022): out./nov./dez.; e-162727
Revista Brasileira de Cancerologia
Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron:INCA

Introduction: Colorectal cancer (CRC) is the second most common and when metastatic, it has a five-year survival rate of 14%. Regorafenib is an approved TKI for metastatic colorectal cancer (mCRC) with a proven increase in overall survival (OS). Obje

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3056::3f19fddcbbb6e4ed077dc0f6341992a0
https://rbc.inca.gov.br/index.php/revista/article/view/2727